[alpha 1-fetoprotein and Tennessee antigen in hepatocellular carcinomas and in metastatic liver cancer (author's transl)].
alpha 1-fetoprotein and Tennessee Antigen were evaluated in sera of 23 patients with hepatocellular carcinomas as well as in 20 patients with extrahepatic carcinomas and liver metastases. The diagnosis as histologically verified in all cases. Altogether 87% out of all hepatoma patients showed increased alpha 1-fetoprotein levels, whereby the concentrations were in the range which is highly suggestive of hepatoma in 65% of all patients with hepatoma. Tennessee Antigen concentrations were increased in 87% of hepatoma patients and in 85% of patients with metastatic liver cancer. Tennessee Antigen is an unspecific tumour marker, which can be used in control assessment during chemotherapy or after tumour resection and is of particular value in the follow up of those patients whose serum alpha 1-fetoprotein concentrations are normal or only slightly increased.
D000951:Antigens, Neoplasm / Q000032:analysis*; D006528:Carcinoma, Hepatocellular / Q000032:analysis / Q000276:immunology / Q000556:secondary*; D006801:Humans; D008113:Liver Neoplasms / Q000032:analysis / Q000276:immunology / Q000556:secondary*; D000509:alpha-Fetoproteins / Q000032:analysis*
D000951:Antigens, Neoplasm; C033814:Tennessee antigen, human; D000509:alpha-Fetoproteins
alpha 1-Fetoprotein und Tennessee-Antigen bei hepatozellulären Karzinomen und bei der Metastasenleber.